EMA/330327/2010

European Medicines Agency decision

P/94/2010

of 2 June 2010

on the agreement of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for peginterferon alfa-2a (Pegasys) (EMEA-000298-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8670
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/94/2010

of 2 June 2010

on the agreement of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for peginterferon alfa-2a (Pegasys) (EMEA-000298-PIP01-08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Roche Registration Ltd on 28 May 2008 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 16 April 2010, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision refusing a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for peginterferon alfa-2a (Pegasys), solution for injection in pre-filled syringe, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for peginterferon alfa-2a (Pegasys), solution for injection in pre-filled syringe, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby refused.

Article 3

A waiver for peginterferon alfa-2a (Pegasys), solution for injection in pre-filled syringe, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Roche Registration Ltd, 6 Falcon Way, Shire Park, AL7 1TW Welwyn Garden City, United Kingdom.

Done at London, 2 June 2010

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

EMA/PDCO/150330/2010

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a waiver and a refusal of a deferral

EMEA-000298-PIP01-08

Scope of the application

Active substance(s):

Peginterferon alfa-2a

Invented name:

Pegasys

Condition(s):

Chronic hepatitis C

Chronic hepatitis B

Pharmaceutical form(s):

Solution for injection in pre-filled syringe

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Roche Registration Ltd

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Roche Registration Ltd submitted for agreement to the European Medicines Agency on 28 May 2008 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

The procedure started on 1 July 2008.

Supplementary information was provided by the applicant on 2 February 2010.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
   - to refuse a deferral in accordance with Article 21 of said Regulation.
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subsets of the paediatric population and conditions covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

London, 16 April 2010

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

Annex I

The measures and timelines of the agreed Paediatric Investigation Plan and the subset(s) of the paediatric population and condition(s) covered by the waiver

1. Condition(s)

Chronic hepatitis C

Chronic hepatitis B

2. Waiver

2.1. Condition

Chronic hepatitis C

The waiver applies to:

- the paediatric population from birth to less than 3 years of age.
- for solution for injection in pre-filled syringe , subcutaneous use
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.

2.2. Condition

Chronic hepatitis B

The waiver applies to:

- the paediatric population from birth to less than 3 years of age.
- for solution for injection in pre-filled syringe , subcutaneous use
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.

3. Paediatric Investigation Plan

3.1. Condition to be investigated

Chronic hepatitis C

3.1.1. Indication targeted by the PIP

Treatment of chronic hepatitis C.

3.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 3 to less than 18 years of age.

3.1.3. Pharmaceutical form(s)

Solution for injection in pre-filled syringe (90, 135 and 180 micrograms)

3.1.4. Studies

Area	Number of studies	Description
Quality	1	1. Development of a 90 µg prefilled syringe for subcutaneous use, with six graduations, to indicate doses of 90, 65, 45, 30, 20, and 10 µg.
Non-clinical		Not applicable.
Clinical	2	2. Multicenter, randomised, placebo-controlled safety and efficacy study of ribavirin in children from 5 to less than 18 year old, treated with peginterferon alfa-2a (NV17424, PEDS-C). 3. Extrapolation study on the efficacy of peginterferon alfa-2a in paediatric patients with Hepatitis C and 1) have failed previous treatment with interferon alpha (pegylated or non-pegylated) alone or in combination therapy with ribavirin, HIV coinfection, or 2) who have HIV coinfection, or 3) who are 3 to less than 5 years of age.

3.2. Condition to be investigated

Chronic hepatitis B

3.2.1. Indication targeted by the PIP

Treatment of chronic hepatitis B.

3.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From 3 to less than 18 years of age.

3.2.3. Pharmaceutical form(s)

Solution for injection in pre-filled syringe (90, 135 and 180 micrograms)

3.2.4. Studies

Area	Number of studies	Description
Quality	1	1. Development of a 90 µg prefilled syringe for subcutaneous use, with six graduations, to indicate doses of 90, 65, 45, 30, 20, and 10 µg (same study as for chronic Hepatitis C).
Non-clinical		Not applicable.
Clinical	2	2. Open-label, randomised, superiority study of the efficacy of peginterferon alfa-2a monotherapy versus no treatment in HBeAg positive children with chronic hepatitis B virus infection (WV18447) 3. Randomised, HBsAg seroconversion study of peginterferon alfa-2a,

Area	Number of studies	Description
		alone or in combination with lamivudine, compared to no treatment, in immunotolerant children, from 3 to 16 years, with chronic hepatitis B.

4. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety issues in relation to paediatric use:	**Yes**
Date of completion of the paediatric investigation plan:	**By March 2014**
Deferral for one or more studies contained in the paediatric investigation plan:	**No**

4.1. Refusal of deferral

The PDCO denied a deferral on the grounds that the results of all studies in this paediatric investigation plan need to be submitted with the next regulatory submissions, as these will be variations to include the two paediatric indications.

Annex II

Information about the authorised medicinal product

EU Number	Invented name	Strength	Pharmaceutical form	Route of administration	Packaging	Content (concentration)	Package size
EU/1/02/221/001	PEGASYS	135 µg	Solution for injection	Subcutaneous use	Vial (glass)	1 ml (135 µg/ml)	1 vial
EU/1/02/221/002	PEGASYS	135 µg	Solution for injection	Subcutaneous use	Vial (glass)	1 ml (135 µg/ml)	4 vials
EU/1/02/221/003	PEGASYS	180 µg	Solution for injection	Subcutaneous use	Vial (glass)	1 ml (180 µg/ml)	1 vial
EU/1/02/221/004	PEGASYS	180 µg	Solution for injection	Subcutaneous use	Vial (glass)	1 ml (180 µg/ml)	4 vials
EU/1/02/221/005	PEGASYS	135 µg	Solution for injection	Subcutaneous use	Pre-filled syringe (glass)	0.5 ml (270 µg/ml)	1 pre-filled syringe + 1 injection needle
EU/1/02/221/006	PEGASYS	135 µg	Solution for injection	Subcutaneous use	Pre-filled syringe (glass)	0.5 ml (270 µg/ml)	4 pre-filled syringes + 4 injection needles
EU/1/02/221/007	PEGASYS	180 µg	Solution for injection	Subcutaneous use	Pre-filled syringe (glass)	0.5 ml (360 µg/ml)	1 pre-filled syringe + 1 injection needle
EU/1/02/221/008	PEGASYS	180 µg	Solution for injection	Subcutaneous use	Pre-filled syringe (glass)	0.5 ml (360 µg/ml)	4 pre-filled syringes + 4 injection needles
EU/1/02/221/009	PEGASYS	135 µg	Solution for injection	Subcutaneous use	Pre-filled syringe (glass)	0.5 ml (270 µg/ml)	12 pre-filled syringes + 12 injection needles
EU/1/02/221/010	PEGASYS	180 µg	Solution for injection	Subcutaneous use	Pre-filled syringe (glass)	0.5 ml (360 µg/ml)	12 pre-filled syringes + 12 injection needles